Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00607347 · ClinicalTrials.gov registry record · NA
Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers
A NA study, sponsored by University of Florida.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT00607347 is a NA study that has completed, run by University of Florida. The registered enrollment target is 24 participants.
The verdict
NCT00607347, a NA study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
The researchers hypothesize that the impact of increasing systemic exposure to atenolol leads to increased risk for adverse metabolic effects from atenolol therapy in hypertension. This will be accomplished through a 24-hour pharmacokinetic (PK) study and oral glucose tolerance test in hypertensive patients taking chronic atenolol 100 mg daily.
Interventions
- OTHER Glucose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-02 |
| Est. Completion | 2009-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00607347
The ClinicalTrials.gov registry entry for NCT00607347 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glucose is the first listed.
NCT00607347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00607347 about?
NCT00607347 is a clinical study titled "Atenolol Exposure as Risk for Adverse Metabolic Responses to Beta Blockers". The researchers hypothesize that the impact of increasing systemic exposure to atenolol leads to increased risk for adverse metabolic effects from atenolol therapy in hypertension. This will be accomplished through a 24-hour pharmacokinetic (PK) study and oral glucose tolerance test in hypertensive ...
What is the current status of trial NCT00607347?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2008-02. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00607347?
The interventions under investigation include: Glucose (OTHER).
Who is sponsoring clinical trial NCT00607347?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.